

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of The  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2026

**LENZ THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-40532**  
(Commission File Number)

**84-4867570**  
(I.R.S. Employer  
Identification No.)

**201 Lomas Santa Fe Dr., Suite 300**  
**Solana Beach, California**  
(Address of principal executive offices)

**92075**  
(Zip code)

**(858) 925-7000**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
<b>Common Stock, par value \$0.00001 per share</b>	<b>LENZ</b>	<b>The Nasdaq Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

LENZ Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders on June 12, 2026 (the “Annual Meeting”). Of the 31,354,394 shares of the Company’s common stock outstanding as of the record date of April 14, 2026, 24,442,068 shares were represented at the Annual Meeting, either by proxy or by attending the meeting. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:

1. **Election of Class II Directors.** The following nominees were elected to serve as Class II directors to hold office until the Company's 2029 annual meeting of stockholders, or until their respective successor has been duly elected and qualified:

Nominee	Votes For	Votes Withheld	Broker Non-Votes
Evert Schimmelpennink	20,216,637	230,219	3,995,212
Jeff George	13,462,359	6,984,497	3,995,212
Shelley Thunen	20,215,686	231,170	3,995,212

2. **Ratification of Appointment of Independent Registered Public Accounting Firm.** The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified based on the following results of voting:

Votes For	Votes Against	Abstentions	Broker Non-Votes
24,310,915	55,181	75,972	—

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LENZ THERAPEUTICS, INC.**

Dated: June 12, 2026

By:	<u>/s/ Daniel Chevallard</u>
Name:	Daniel Chevallard
Title:	Chief Financial Officer (Principal Financial and Accounting Officer)